CASI Pharmaceuticals Secures China Drug Registration for Thiotepa Ahead of Planned Asset Disposal

The latest announcement is out from CASI Pharmaceuticals ( (CASI) ).

On February 10, 2026, CASI Pharmaceuticals reported that its China subsidiary received a Drug Registration Certificate from the National Medical Products Administration for Thiotepa for Injection, with the approval valid until February 1, 2031. The company holds exclusive distribution rights in mainland China for Thiotepa from ESTEVE Pharmaceuticals and has previously disclosed plans to dispose of its Thiotepa-related rights and certain other pipeline assets to Kaixin Pharmaceuticals, underscoring a potential strategic shift in its product portfolio and revenue mix in the China market.

The most recent analyst rating on (CASI) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.

The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq that focuses on developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. The company operates primarily in China, where it also manages in-licensed oncology and specialty therapies through exclusive distribution arrangements.

Average Trading Volume: 35,998

Technical Sentiment Signal: Sell

Current Market Cap: $14.33M

See more insights into CASI stock on TipRanks’ Stock Analysis page.